

Lacnotuzumab

Cat. No.:	HY-P99368
CAS No.:	1831128-32-5
Target:	c-Fms
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/k monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis ^{[1][2]} .
IC ₅₀ & Target	CSF-1 ^[1]
In Vivo	Lacnotuzumab neutralizes recombinant and serum-derived forms of cynomolgus CSF-1, but it does not recognize rodent or rabbit CSF-1 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. *Clin Cancer Res.* 2022 Jan 1;28(1):106-115.

[2]. Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. *J Pharmacol Exp Ther.* 2019 Jun;369(3):428-442.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA